Open Clinical Trials:
CLINICAL TRIAL 19627
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
Disease Site: Lymphoma, Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 19715
An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Mosunetuzumab (Btct4465a) In Combination With Polatuzumab Vedotin In Patients With B-Cell Non-Hodgkin Lymphoma
Disease Site: Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 20069
A Phase 1, Multi-center, Open-label, Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of an Orally Available Small Molecule CC-99282 Alone and in Combination with Rituximab in Subjects with Relapsed and/or Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL) and Indolent Non-Hodgkin Lymphoma (R/R iNHL)
Disease Site: Lymphoid Leukemia, Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 20385
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin(Adcetris) Plus AVD in Patients (Age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Disease Site: Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 20571
Optimizing Cellular and Humoral Immunity to Pneumococcus by Vaccination with Pneumococcal 13-valent conjugate vaccine before and after CD19-targeted CAR T-cell Immunotherapy
Disease Site: Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 20578
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmocodynamics of ALLO-501A, an Anti-CD19 Allogeneic Car T Cell Therapy in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Disease Site: Lymphoma, Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 20608
A Phase 1/2 Study Evaluating the Safety and Efficacy of IOV-2001 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Disease Site: Chronic Leukemia (CLL, CML), Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 20737
Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel That is Nonconforming for Commercial Release
Disease Site: Hodgkin's Lymphoma, Lymphoid Leukemia, Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 20751
A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma
Disease Site: Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 21094
An Open Label, Multi-Cohort, Multi-Center Phase II Study Evaluating the Efficacy and Safety of IPH4102 Alone or in Combination with Chemotherapy in Patients with Advanced T-cell Lymphoma
Disease Site: Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 21096
A Phase I Study of Duvelisib in Combination with CC-486 in Lymphoid Malignancy
Disease Site: Lymphoid Leukemia, Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 21122
A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Disease Site: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 90001
A Phase 2, Multicenter, Single-Arm Study of Retreatment with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classic Hodgkin lymphoma (cHL) or CD30-Expressing Peripheral T Cell Lymphoma (PTCL)
Disease Site: Hodgkin's Lymphoma
View Trial DetailsCLINICAL TRIAL 20067
INSPIRE: A Multicenter Randomized Controlled Trial Integrating Health Informatics in a Scalable Stepped Care Self-Management Program for Survivors after Hematopoietic Cell Transplantation
Disease Site: Hodgkin's Lymphoma, Leukemia, other, Lymphoid Leukemia, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Other Hematopoietic
View Trial DetailsCLINICAL TRIAL 20397
A Phase 2 Study of Itacitinib, for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy
Disease Site: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
View Trial Details